Nuclear expression of Lyn, a Src family kinase member, is associated with poor prognosis in renal cancer patients by Antonia K. Roseweir et al.
RESEARCH ARTICLE Open Access
Nuclear expression of Lyn, a Src family
kinase member, is associated with poor
prognosis in renal cancer patients
Antonia K. Roseweir1, Tahir Qayyum1, Zhi Lim1, Rachel Hammond1, Alasdair I. MacDonald1, Sioban Fraser2,
Grenville M. Oades2, Michael Aitchison3, Robert J. Jones4 and Joanne Edwards1*
Abstract
Background: 8000 cases of renal cancer are diagnosed each year in the UK, with a five-year survival rate of 50 %.
Treatment options are limited; a potential therapeutic target is the Src family kinases (SFKs). SFKs have roles in
multiple oncogenic processes and promote metastases in solid tumours. The aim of this study was to investigate
SFKs as potential therapeutic targets for clear cell renal cell carcinoma (ccRCC).
Methods: SFKs expression was assessed in a tissue microarray consisting of 192 ccRCC patients with full clinical
follow-up. SFK inhibitors, dasatinib and saracatinib, were assessed in early ccRCC cell lines, 786-O and 769-P and a
metastatic ccRCC cell line, ACHN (± Src) for effects on protein expression, apoptosis, proliferation and wound
healing.
Results: High nuclear expression of Lyn and the downstream marker of activation, paxillin, were associated with
decreased patient survival. Conversely, high cytoplasmic expression of other SFK members and downstream marker
of activation, focal adhesion kinase (FAK) were associated with increased patient survival. Treatment of non-metastatic
786-O and 769-P cells with dasatinib, dose dependently reduced SFK activation, shown via SFK (Y419) and FAK (Y861)
phosphorylation, with no effect in metastatic ACHN cells. Dasatinib also increased apoptosis, while decreasing
proliferation and migration in 786-O and 769-P cell lines, both in the presence and absence of Src protein.
Conclusions: Our data suggests that nuclear Lyn is a potential therapeutic target for ccRCC and dasatinib
affects cellular functions associated with cancer progression via a Src kinase independent mechanism.
Keywords: Renal cell carcinoma, Src family kinases, Paxillin, Dasatinib, Apoptosis, Phosphorylation, Wound
healing, Human cell lines
Background
In the UK, 8000 new cases of clear cell renal cancer
(ccRCC) are diagnosed each year; survival rates are poor,
with estimated five-year survival rates at only 50 %.
Currently the mainstay drug therapy for advanced renal
cancer is vascular endothelial growth factor receptor
tyrosine kinase inhibitors (VEGFR TKi, such as suniti-
nib, pazopanib and axitinib) and inhibitors of mamma-
lian target of rapamycin (mTOR, such as everolimus or
temsirolimus) [1–3]. Despite these recent advances, the
outlook for these patients remains poor with little pro-
spect of a cure. Further insights into activated signalling
pathways in renal cancer will help guide development of
improved therapies.
The non-receptor tyrosine kinase Src is associated
with multiple oncogenic cellular processes including mi-
gration, adhesion, invasion, proliferation and survival
[4]. Src kinase is the prototypical member of the Src
family kinases (SFKs), with a total of 8 members
expressed in mammalian cells (Src, Blk, Fgr, Fyn Yes,
Hck, Lck & Lyn). Autophosphorylation of the Y419 site
in the kinase domain of Src can be used as a marker of
activation; however due to high levels of similarity in this
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region between SFKs, the Y419 site is not specific to Src,
but is associated with activation of all family members
[5, 6]. Therefore, autophosphorylation of Y419 cannot be
assumed to represent only Src kinase activation, instead
all SFKs need to be investigated to dissect out which
member is being affected in different tumours.
SFKs are elevated in various malignancies including
prostate, breast, colon and lung [7–10]; however de-
pending on the tumour type they can be associated with
good or poor prognosis [8]. To date there is limited evi-
dence examining SFK expression in renal cancer. Suwaki
et al. (2011) reported that in metastatic renal cancer the
HIF-regulated VHL-PTP1B-Src kinase signalling path-
way determines the sensitivity of tumours to the SFK in-
hibitor, dasatinib [11]. Previous work in our laboratory
observed that SFKs are expressed at their highest level
in T2 stage carcinomas, suggesting that the SFK pathway
is active in ccRCC prior to development of metastasis
[12]. Accordingly, there is a need to establish which SFKs
are associated with poor prognosis in ccRCC and to deter-
mine the mechanisms of action of SFK inhibitors in early
(non-metastatic) and late (metastatic) stage tumours.
The aims of the current study were to evaluate
whether SFKs and downstream markers of activation
were associated with ccRCC patient prognosis and to in-
vestigate the functional effects of two SFK inhibitors,
dasatinib and saracatinib, in non-metastatic and meta-
static ccRCC cell lines.
Methods
Materials
Dasatinib and saracatinib were obtained from Selleck
Chemicals (Texas, USA). Src ONTarget Plus smartpool
small interfering ribonucleic acid (siRNA) and non-
targeting (NT) ONTarget Plus siRNA #1 were acquired
from Thermo Fisher Scientific Biosciences GMBH
(Loughborough, UK). All other reagents were obtained
from Sigma, UK unless otherwise stated in the text.
Patient cohort
The tissue microarray (TMA) consisted of 192 patients
diagnosed with ccRCC within the Greater Glasgow NHS
Trust between 1997 and 2008; all patients gave informed
consent prior to biopsy for samples to be used for
research purposes. These patients had undergone
complete resection of the tumour at the time of neph-
rectomy. Patients were staged pathologically and graded
according to the TNM classification and Fuhrman grad-
ing respectively. The research ethics committee of West
of Scotland approved the study (GN10SU229).
Immunohistochemistry
Antibodies were validated by a single band on a western
blot and with antibody blocking experiments on renal
tissue sections. TMA sections were de-waxed and rehy-
drated through graded alcohols then antigen retrieval
was performed by heating TMA sections under pressure
for 5 min using either citrate buffer pH6 (Src kinase,
focal adhesion kinase (FAK, Y861), FAK (Y397), Fyn, Hck,
Lck, Yes) or Ethylenediaminetetraacetic acid (EDTA)
buffer pH9 (Src (Y419), paxillin, Lyn, Fgr). TMA sections
were blocked with 3 % hydrogen peroxide followed by
5 % normal horse serum (Vector Laboratories, USA) in
antibody diluent (DAKO, Denmark) for 20 min at room
temperature. Incubation with primary antibody for
60 min at room temperature for Src kinase (1:200) and
Fgr (1:4000, Cell Signaling Technologies. USA) or over-
night at 4 °C for Src (Y419; 1:25, Millipore, UK), FAK
(Y861; 1:200, Invitrogen, UK), FAK (Y397; 1:200, Abcam,
UK), Fyn (1:1500), Lyn (1:25), Hck (1:1000), Lck (1:200),
Yes (1:150) and paxillin (1:25, Cell Signaling Technologies,
USA). Protein expression was amplified and visualized
using DAKO envision kit (DAKO, USA) and Chromogen
3,3’-diaminobenzidine (DAB, Vector Laboratories, USA).
Sections were counterstained with haematoxylin,
dehydrated and mounted. Protein expression was in-
dividually assessed at the membrane, cytoplasm and
nucleus for each core (three per tumour specimen)
using the weighted histoscore method by two inde-
pendent observers and agreement between observers
was calculated using the interclass correlation co-
efficient [13]. The average score for each cellular lo-
cation within individual tumours was calculated and
divided into high expression (above median) or low
expression (below median).
Cell culture
786-O (ATCC®, CRL-1932™) and 769-P (ATCC®, CRL-
1933™) early non-metastatic ccRCC cells were main-
tained in RPMI-1640 medium supplemented with 10 %
foetal calf serum, 1 % Glutamax and 1 % Penicillin
(10,000 Units/ml)/Streptomycin (10,000 Units/ml). ACHN
metastatic ccRCC cells (ATCC®, CRL-1611™) were main-
tained in Essential Modified Eagle's Medium (EMEM)
supplemented with 10 % Foetal calf serum, 1 % Glutamax
and 1 % Penicillin (10,000 Units/ml)/Streptomycin
(10,000 Units/ml). Cells were authenticated using short
tandem repeat DNA profiling. Prior to treatment or
siRNA transfection, cells were seeded at a density of
1×105 cells/well for 6-well plates and 5×103 cells/well for
96-well plates then incubated at 37 °C with 5 % CO2 in air
for 24 h. Inhibitor treatments were then performed as ap-
propriate; dasatinib was added for 48 h and saracatinib for
24 h at 37 °C with 5 % CO2 in air.
siRNA transfection
200 nM NT control or Src siRNA was transfected into
cells using lipofectamine siRNAMax in optimem-1 as
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per manufacturer’s instructions and cells incubated at
37 °C with 5 % CO2 in air for 72 h. After 8 h incubation,
the media was changed to RPMI-1640 or EMEM media
and inhibitor treatments performed as appropriate.
Preparation of cellular extract and immunoblotting
Cell lysates and electrophoresis was performed as
previously described [7]. Immunoblotting of Src
(Y419; Millipore, USA) [14], Src kinase (Cell Signaling
Technology, USA) [15], FAK (Y861; Invitrogen, UK) [16]
and FAK (Y397; Abcam, UK) [17] were performed at
1:1000 dilutions with rabbit anti-human antibodies. Pro-
teins were visualized by addition of a 1:5000 dilution of
horseradish peroxidase (HRP)-conjugated polyclonal anti-
rabbit IgG. HRP-conjugated antibodies raised against beta
tubulin were used as loading controls. HRP-conjugated
protein was visualized using an enzyme-linked chemilu-
minescence reaction (Thermo Fisher Scientific, UK) and
Table 1 Clinicopathological characteristics for ccRCC patient cohort and disease specific survival (n = 192)
Univariate survival analysisb Multivariate survival analysisc
Disease specific survival Disease specific survival





Age (≤61/>61) 94 (49)/98 (51) 0.97 (0.50–1.86) 0.916
T-stage (I/II/III/IV) 83 (43)/33 (17)/69 (36)/7 (4) 2.13 (1.46–3.12) 9.4×10−5
Grade (I/II/III/IV) 15 (8)/59 (30)/84 (44)/34 (18) 2.16 (1.40–3.35) 0.001 1.56 (1.02–2.40) 0.042
Recurrence (None/recurred) 142 (74)/50 (26) 11.47 (5.22–25.20) 6.78×10−15 12.50 (5.09–30.64) 1.0×10−7
KLINTRUP (Low/High) 96 (50)/96 (50) 0.97 (0.50–1.87) 0.932
aCI = Confidence Interval
bUnivariate analysis was performed using the Log Rank Test
cMultivariate analysis was performed using Cox Regression
P-values in bold are greater than the significance threshold of 0.05
Fig. 1 High membrane expression of SFK pathway members increases disease specific survival in a ccRCC patient cohort. a Representative
pictures showing membrane, cytoplasmic and nuclear staining for SFK family members and downstream targets. (b–d) Kaplan Meier curves
showing high membrane expression of (b) Fyn and (c) Hck and (d) Yes significantly increased disease specific survival by 2–3 years in a cohort of
192 ccRCC patients. e Kaplan Meier showing high levels of FAK phosphorylation at Y861 within the cellular membrane also increases disease
specific survival by 2–3 years. Data shown is the average histoscore for 3 cores per patient and significance was set at 0.05
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quantified using a LAS3000 image analyser (Fujifilm,
Tokyo) and analysed with Image J software (NIH, US).
WST-1 proliferation assay
Cell viability was measured by mitochondrial dehydro-
genase induced cleavage of water soluble tetrazolium salt
(WST), via incubation with WST-1 for 2 h at 37 °C with
5 % CO2 in air (Roche Applied Science, UK). Absorb-
ance was then measured at 450 nm.
Cell death detection ELISA Plus
Cell Death Detection ELISA Plus kits (Roche Applied
Science, UK) were used to measure apoptosis by
quantifying histone-DNA complexes generated after
inhibitor treatment, as per the manufacturer’s protocol.
HRP cleavage of 2,2-azinobis(3-ethylbenzothiazoline-6-
sulphonic acid, ABTS) substrate was measured by absorb-
ance at 405 nm.
Wound healing assay
Cell monolayers had scratches created with a pipette tip
and were washed twice with PBS. Cells were then treated
with inhibitors and incubated at 37 °C with 5 % CO2 in
air for 20 h. Cell scratches were photographed at 0 and
20 h and the width of the scratch recorded using an
Olympus IX51 microscope. The distance refilled be-
tween the furthest migrated cell and the scraped edge on
both sides was used to evaluate migration.
Statistical analysis
For immunohistochemistry, disease specific survival
(DSS) curves, which represents the time to a cancer-
specific death from diagnosis, was generated using the
Kaplan-Meier method. The log rank test was utilized to
compare significant differences between subset groups
using univariate analysis. Multivariate Cox regression
analysis was performed to identify those factors that
were independently associated with disease specific
survival.
All other assays were analysed using a two-way
ANOVA followed by Bonferroni post-hoc tests. Statis-
tical significance was set at p < 0.05 and experiments
were repeated three times.
Results
Localisation-dependant associations between disease
specific survival and SFK pathway
The relationship between clinicopathological characteris-
tics of patients with ccRCC and disease specific survival
is shown in Table 1. In agreement with previous work,
SFKs were expressed at highest levels in T2 patient tu-
mours (data not shown).
Expression was independently assessed in cell mem-
branes, cytoplasm and nuclei for each protein investigated
Table 2 Protein expression for SFKs and downstream markers
of activation and disease specific survival (n = 192)
Protein Median (IQRa) p-value
Src Kinase
Membrane 50 (27–80) 0.237
Cytoplasmic 37 (27–68) 0.132
Nucleus 2 (0–12) 0.726
SFK (Y416)
Membrane 5 (0–13) 0.206
Cytoplasmic 7 (0–20) 0.868
Nucleus 2 (0–11) 0.735
FAK (Y861)
Membrane 13 (3–37) 0.008
Cytoplasmic 7 (0–20) 0.546
Nuclear 60 (43–77) 0.532
FAK (Y397)
Membrane 93 (41–147) 0.001
Cytoplasmic 77 (33–133) 0.252
Nuclear 152 (127–180) 0.846
Paxillin
Membrane 3 (0–10) 0.050
Cytoplasmic 7 (0–10) 0.335
Nuclear 3 (0–63) 0.031
FYN
Membrane 15 (2–30) 0.006
Cytoplasmic 8 (2–17) 0.393
Nuclear 13 (0–109) 0.139
LYN
Membrane 37 (10–77) 0.141
Cytoplasmic 70 (38–202) 0.446
Nuclear 13 (0–109) 0.019
FGR
Membrane 7 (0–22) 0.087
Cytoplasmic 33 (15–60) 0.252
Nuclear 9 (3–27) 0.503
HCK
Membrane 63 (27–103) 0.038
Cytoplasmic 47 (30–27) 0.109
Nuclear 57 (30–80) 0.197
YES
Membrane 47 (17–70) 0.0004
Cytoplasm 38 (23–69) 0.271
Nucleus 43 (27–62) 0.842
aIQR = interquartile range
P-values in bold are greater than the significance threshold of 0.05
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(Fig. 1a). Patients whose tumours expressed high levels of
membrane Fyn (p = 0.006), Hck (p = 0.038) and Yes
(0.0004) were observed to have a significantly longer dis-
ease specific survival compared to those patients whose
tumours expressed low levels of these SFK (Fig. 1b-d).
In addition, high levels of phosphorylated FAK (Y861,
p = 0.008), a downstream marker of activation, were
also associated with good prognosis (Fig. 1e). No sig-
nificant associations were observed for membrane ex-
pression and any other protein investigated (Table 2).
When membrane expression of these significant find-
ings was entered into multivariate cox regression
model with tumour stage, tumour grade and recur-
rence, high membrane Yes expression (p = 0.014) was
demonstrated to be independent of other factors in
the model. No significant observations were made be-
tween survival and cytoplasmic expression of any pro-
teins investigated (Table 2).
In contrast to the association with good prognosis ob-
served in the membrane, patients with tumours that
expressed high levels of nuclear Lyn or Paxillin (down-
stream marker of activation) had significantly shorter
disease specific survival compared to patient tumours
expressing low levels (p = 0.019 & p = 0.028, Fig. 2a-b).
When nuclear expression of Lyn and Paxillin were en-
tered into multivariate cox regression model with
tumour stage, tumour grade and recurrence high mem-
brane Lyn expression (p = 0.011) was demonstrated to
be independent of other factors in the model.
Dasatinib and saracatinib affect the SFK pathway in early
ccRCC cell lines
In the early non-metastatic, 769-P and 786-O ccRCC
cell lines, dasatinib significantly inhibited SFK phosphor-
ylation at Y419, however saracatinib has no effect.
Neither inhibitor affected the total amount of Src kinase
in the cell. However, dasatinib and saracatinib did inhibit
phosphorylation of the downstream marker of activation
FAK at the Src-dependent site Y861, although only dasa-
tinib reached statistical significance (Fig. 3a–c). Dasati-
nib also caused a significant dose dependent increase in
phosphorylation of FAK at the auto-phosphorylation site
Y397 in non-metastatic 769-P and 786-O cells (Fig. 3a–c).
No effect of either inhibitor was noted in the metastatic
ACHN cells (Fig. 3a, d).
SFK inhibitors affect cellular functions associated with
cancer progression
Dasatinib showed a significant dose dependent re-
sponse on apoptosis, proliferation and motility in
early non-metastatic 769-P and 786-O ccRCC cell
lines (Fig. 4). In contrast in saracatinib treated cells,
there was no statistically significant response observed
for any of these functional outputs; however, there
was a trend towards inhibition of wound healing
(Fig. 4c, d, f ). In metastatic ACHN cells, only wound
healing was significantly affected by dasatinib and sar-
acatinib (Fig. 4e, f ).
SFK inhibitors do not act via the prototypical SFK, Src
kinase, in early RCC cells
In early non-metastatic 769-P and 786-O ccRCC cells,
src kinase was silenced using SMARTpool siRNA, with a
knockdown of approximately 85 % for both cell lines
(Fig. 5a). In silenced 769-P and 786-O cells, dasatinib
significantly decreased proliferation to a similar extent
to that seen in the non-silenced cells (Fig. 5b). Similarly,
dasatinib still increased apoptosis and inhibited wound
healing in 769-P silenced cells, as did saracatinib
(Fig. 5c-f).
Fig. 2 High nuclear Lyn and paxillin expression decreases disease specific survival for patients with ccRCC. Kaplan Meier curves showing that high
nuclear expression of (a) Lyn and (b) Paxillin significantly decreased disease specific survival by 2–3 years in a cohort of 192 ccRCC patients. Data
shown is the average histoscore for 3 cores per patient and significance was set at 0.05
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Discussion
In the current study, the role of SFK in ccRCC were in-
vestigated. High nuclear expression of Lyn and down-
stream paxillin was associated with poor prognosis in
our patient cohort and cell line studies demonstrated
that dasatinib could induce apoptosis and inhibit prolif-
eration. Nuclear accumulations of Lyn and paxillin have
previously been observed in solid tumours and are both
associated with inducing cell proliferation [18]. Lyn
was reported to increase cell proliferation in breast can-
cer cell lines [18], via binding to and phosphorylating
epidermal growth factor receptor (EGFR) in the cyto-
plasm and chaperoning EGFR translocation to the
nucleus, whereby Lyn acted as a transcription factor in
the up-regulation of expression of Cyclin D1, inducible
nitric oxide synthase (iNOS) and other pro-oncogenic
factors [18]. Both the nuclear accumulation of Lyn and
induction of proliferation could be blocked by dasatinib
[19]. Therefore, we hypothesis that a similar process
may occur in ccRCC as nuclear Lyn is associated with
poor prognosis in our clinical specimens and dasatinib
induces apoptosis and inhibits cell proliferation and mi-
gration in ccRCC cell lines independent of Src kinase.
Nuclear paxillin has also been observed to increase cell
proliferation via transcription of Cyclin D1 in prostate
cancer cells, by acting as a nuclear scaffold, to promote
Fig. 3 SFK inhibitors affect phosphorylation in non-metastatic ccRCC cell lines. a Western blots showing the effect of control (C), 10 % Serum (V),
1, 10, 50 or 100 nM dasatinib or saracatinib on SFK (Y416), FAK (Y861) and Src kinase in the non-metastatic, 769-P and 786-O and metastatic ACHN
cells. b–d Quantification of western blot results for dasatinib (black bars) and saracatinib (grey bars) in (b) 769-P, (c) 786-O and (d) ACHN cells
(n = 3-4: * = 0.05, ** = 0.01, *** = 0.001)
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extracellular-regulated kinase (ERK) phosphorylation of
the ETS domain-containing protein (Elk-1) [20]. Paxillin
may therefore be acting as a scaffold within a SFK pro-
tein complex in ccRCC; however this requires further in-
vestigation. Overall, these results suggest, inhibition of
Lyn may have therapeutic potential in ccRCC, but fur-
ther mechanistic studies are required to confirm these
findings. Furthermore, dasatinib may not be the appro-
priate inhibitor to employ clinically due to the associa-
tions we observed with good prognosis and other family
members. Development of inhibitors selective for Lyn
over other family members may be more clinically
relevant.
In addition to the poor prognosis observed in this
study with nuclear Lyn and paxillin, good prognosis was
also observed with membrane expression of Fyn, Hck,
Yes and activated FAK, stressing the importance of ana-
lysing different cellular localization for SFKs in ccRCC.
As Fyn and Yes are known to associated with FAK at the
cell membrane, it was reassuring that all three were
Fig. 4 Dasatinib affects multiple oncogenic processes in non-metastatic ccRCC cell lines. a-b Graph showing the effect of 1, 10, 50 and 100 nM
dasatinib (black bars) or saracatinib (grey bars) on (a) proliferation and (b) apoptosis in non-metastatic, 769-P and 786-O and metastatic ACHN
cells. c-e Photographs and (f) quantification graphs showing the effect of the inhibitors on migration as measured via wound healing in the
three cell lines (n = 3; * = 0.05, ** = 0.01, *** = 0.001)
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Fig. 5 Dasatinib does not function via Src kinase in non-metastatic ccRCC cell lines. a Western blots and showing siRNA knockdown of NT or Src kin-
ase in 769-P and 786–O. b-c Graph showing effect of 1, 10, 50 and 100 nM Dasatinib (dark bars) and saracatinib (light bars) on (b) proliferation and (c)
apoptosis in the presence of NT (solid bars) and Src siRNA (checked bars) in 769-P and 786-O cells. d, e Photographs and (f) quantification graphs
showing effects of inhibitors on migration as assessed by wound healing in 769-P and 786-O cells (n = 3-4; * = 0.05, ** = 0.01, *** = 0.001)
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associated with the same prognosis; however it has pre-
viously been reported that their role was to regulate cell
adhesion, migration, and invasion in response to integ-
rins, which would lead to poor prognosis [18]. In the
current study we have observed that Fyn, Hck, Yes and
activated FAK are all associated with good prognosis and
to date their role as potential tumour suppressors within
this complex has not been widely investigated, and re-
veals a potential new role for these SFKs in ccRCC.
The current study did not observe any significant asso-
ciation between cytoplasmic localisation of any SFK or
activated FAK and DSS. This is in contrast to previous
work within our laboratory which showed that cytoplas-
mic FAK (Y861) was significantly associated with de-
creased DSS. This difference may be a result of the
differing cohort sizes as the initial study only included
57 patient whereas this study includes 192, therefore the
association seen in the smaller cohort may have been di-
luted out as the cohort size has increased.
The current study observed that dasatinib affects acti-
vation of SFKs via phosphorylation at Y419 to increase
apoptosis and decrease proliferation but not saracatinib.
Dasatinib may achieve this by blocking the Src hom-
ology 2 (SH2) domain of its target SFK inhibiting bind-
ing of auto-phosphorylated FAK (Y397), which is
required for SFK activation via phosphorylation at Y419.
Therefore, the observed increase in FAK phosphoryl-
ation at Y397 may be a compensatory mechanism to
swamp the SFK SH2 domain with FAK (Y397) to over-
come dasatinib inhibition. The data also suggests that
saracatinib acts at a different site within the protein that
does not interfere with the SH2 domain binding of FAK
or the Y419 phosphorylation site. Both inhibitors were
observed to be active in the early 786-O and 769-P cell
lines and not the metastatic ACHN cells. This is most
likely due to our groups previously reported observation
that SFKs are highly expressed in T2 stage tumours to
stimulate cell migration and invasion (similar to the
786-O and 769-P cells). However, once the cells have
metastasised levels of SFKs are down-regulated to nom-
inal levels (equivalent to the ACHN cells) [12]. There-
fore, although SFKs are present in ACHN cells they may
not be active. Further investigation is required to con-
firm this hypothesis.
Conclusions
In conclusion, cellular localization of SFKs in ccRCC tu-
mours appears to be a significant factor influencing their
role as a tumour suppressor or enhancer. Lyn and paxil-
lin may be potential biomarkers to select the patients
most likely to benefit from treatment with SFK inhibi-
tors such as dasatinib. However, development of inhibi-
tors specific for different SFKs could be an attractive
novel therapeutic approach for ccRCC patients.
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